A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
Purpose
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Conditions
- Wet Age Related Macular Degeneration
- wAMD
Eligibility
- Eligible Ages
- Over 50 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Previously treated or treatment naïve patients with a documented diagnosis of wAMD in the study eye, with onset of disease that began at any time prior to the Screening Visit. - Best Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) letter score between 78 to 35 letters (approximately 20/32 to 20/200 Snellen equivalent) in the study eye at the Screening Visit and on Baseline (Day 1). - For previously-treated subjects, must have been treated with at least 2 anti-VEGF IVT injections (i.e., aflibercept 2 mg, aflibercept 8 mg, bevacizumab, ranibizumab, or faricimab) in the previous 6 months for wAMD per standard of care in the study eye prior to the Screening Visit.
Exclusion Criteria
- Subfoveal fibrosis, atrophy, or scarring in the center subfield. - BCVA using ETDRS charts <20 letters (20/400 Snellen equivalent) in the fellow eye.
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Experimental EYP-1901 2686 µg |
EYP-1901 |
|
Active Comparator Aflibercept |
|
Recruiting Locations
Gilbert, Arizona 85297
Phoenix, Arizona 85020
Phoenix, Arizona 85050
Scottsdale, Arizona 85255
Arcadia, California 91006
Beverly Hills, California 90211
Encino, California 91436
Fullerton, California 92835
Glendale, California 91204
Huntington Beach, California 92647
Long Beach, California 90807
Modesto, California 95356
Mountain View, California 94040
Oakland, California 94611
Oxnard, California 93036
Redlands, California 92373
Riverside, California 45580
Sacramento, California 95825
Torrance, California 90503
Colorado Springs, Colorado 80909
Lakewood, Colorado 80228
Clearwater, Florida 33761
Deerfield Beach, Florida 33064
Fort Lauderdale, Florida 33308
Fort Myers, Florida 33912
Largo, Florida 33770
Palm Beach Gardens, Florida 45674
Plantation, Florida 33324
St. Petersburg, Florida 33711
Stuart, Florida 34994
Bloomington, Illinois 60616
Oak Park, Illinois 60304
Plainfield, Illinois 60586
Carmel, Indiana 46032
Lexington, Kentucky 40509
Louisville, Kentucky 40206
Metairie, Louisiana 70006
West Monroe, Louisiana 71291
Hagerstown, Maryland 21740
Hagerstown, Maryland 21740
Worcester, Massachusetts 01605
Independence, Missouri 64081
Bloomfield, New Jersey 07003
Cherry Hill, New Jersey 08034
Edison, New Jersey 08820
New York, New York 45604
Westbury, New York 11590
Cary, North Carolina 27511
Hickory, North Carolina 28602
Wake Forest, North Carolina 27587
Edmond, Oklahoma 73013
Portland, Oregon 97239
Springfield, Oregon 97477
Bethlehem, Pennsylvania 18017
Monroeville, Pennsylvania 45674
Ladson, South Carolina 29456
Rapid City, South Dakota 45526
Nashville, Tennessee 37203
Amarillo, Texas 79106
Arlington, Texas 76012
Austin, Texas 45674
Austin, Texas 78705
Austin, Texas 78750
Beaumont, Texas 77707
Burleson, Texas 76028
Dallas, Texas 75243
Houston, Texas 77027
Katy, Texas 77494
Mcallen, Texas 78503
Plano, Texas 75024
San Antonio, Texas 78154
San Antonio, Texas 78240
Tyler, Texas 75703
Falls Church, Virginia 22046
Warrenton, Virginia 20186
Bellevue, Washington 98004
More Details
- NCT ID
- NCT06683742
- Status
- Recruiting
- Sponsor
- EyePoint Pharmaceuticals, Inc.